INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
INVESTED is a randomized, double-blind, multicenter trial to assess the cardiopulmonary benefit of high dose comparted with standard dose influenza vaccine in a high-risk cardiovascular population. Potential subjects must have a history of Myocardial infarction in the previous 12 months OR history of heart failure hospitalization in the previous 24 months. Subjects will be randomized in a 1:1 ratio to high dose or standard dose. Total trial duration is 5 years including site initiation, a Vanguard season followed by 3 influenza seasons, and follow up until the end of the last influenza recruiting season.
PI: Dr. Geoffrey Gorse
Study Coordinator: Peggy Donovan
This study is now closed to enrollment and data analysis is completed. To view the results from this study go to clinicaltrails.gov
This study was funded by the Foundation through NIH (National Institute of Health).
PI: Dr. Geoffrey Gorse
Study Coordinator: Peggy Donovan
This study is now closed to enrollment and data analysis is completed. To view the results from this study go to clinicaltrails.gov
This study was funded by the Foundation through NIH (National Institute of Health).